Related Experiment Video
Updated: May 26, 2026
06:12
Production of Double-stranded DNA Ministrings
Published on: February 29, 2016
Plasmid DNA production for therapeutic applications
Alvaro R Lara1, Octavio T Ramírez, Martin Wunderlich
1Departamento de Procesos y Tecnología, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico City, Mexico. alara@correo.cua.uam.mx
Methods in Molecular Biology (Clifton, N.J.)
|December 14, 2011
Summary
Plasmid DNA (pDNA) is crucial for novel vaccines and gene therapies. Enhancing pDNA production yield is vital for reducing manufacturing costs and increasing accessibility, especially for developing nations.
Area of Science:
- Biotechnology
- Molecular Biology
- Vaccinology
Background:
- Plasmid DNA (pDNA) is foundational for DNA vaccines and gene therapies targeting diverse diseases like HIV-AIDS, Ebola, Malaria, and cancer.
- DNA vaccines offer advantages over conventional vaccines, including high stability, safety, targeted immune response, and long-term protection.
- There is a growing demand for pDNA, particularly in developing countries, due to the need for new, affordable, and effective vaccines.
Purpose of the Study:
- To review the stages of plasmid DNA production, from vector design to downstream processing.
- To discuss recent advancements in cell engineering aimed at improving plasmid DNA production yields.
- To address the need for increased pDNA product yield to reduce manufacturing costs.
Main Methods:
- Review of plasmid DNA production processes, including vector design and downstream operations.
- Analysis of recent cell engineering strategies for enhanced pDNA manufacturing.
- Discussion of methods to increase product yield for cost reduction.
Main Results:
- Plasmid DNA production involves multiple stages, each offering opportunities for optimization.
- Cell engineering presents significant potential for improving pDNA yields.
- Higher pDNA yields are essential for making DNA vaccines and therapies more economically viable.
Conclusions:
- Optimizing plasmid DNA production is critical for the widespread application of DNA vaccines and gene therapies.
- Advancements in cell engineering are key to achieving higher pDNA yields and reducing production costs.
- Increased pDNA availability will support the development and accessibility of novel medical treatments globally.
Related Concept Videos
01:28Plasmids
Plasmids are extrachromosomal DNA molecules found in bacteria, archaea, and some eukaryotic microbes like yeast. These small, circular DNA structures typically contain fewer than 30 genes, although some may exist linearly. Plasmids vary in their number within a cell, known as copy number. Single-copy plasmids are present in one copy per cell and multi-copy plasmids are present in multiple copies, reaching over 100 copies per cell.Plasmids usually replicate independently of the chromosomal DNA...
01:09Recombinant DNA
Overview
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...